PuraPharm Corp. Ltd. 1498

Key Stats for Eli Lilly StockCurrent Price: $1,149. 85Target Price (Mid): ~$2,010Street Target: ~$1,330Potential Total Return: ~75%Annualized IRR: ~14% / yearWhat Happened?Eli Lilly (LLY:NYSE) released Phase 2b results for EloraTZP on September 30.

Key Stats for Pfizer StockCurrent Price: $28. 12Street Target (Mean): ~$29Next Earnings: November 3, 2026What Happened?Florida’s attorney general sued Pfizer (PFE:NYSE) and CEO Albert Bourla on Thursday, October 1, alleging the company misled consumers about its COVID-19 vaccine.

Continued improvement: An increased response was seen in participants on litifilimab from week 24 through week 52, with more individuals achieving clear or almost clear skin (27.2%; CLA IGA 0-1) and improvements in disease activity (28.8%; CLASI-70) than at week 24 (19.0% and 21.7%, respectively)Rapid onset: Participants that switched from placebo to litifilimab experienced improvements in skin disease activity in as early as four weeks -- consistent with results seen in participants who started

NEW YORK, October 02, 2026--Pfizer Inc. (NYSE: PFE) today presented results from two Phase 3 trials evaluating the efficacy and safety of LITFULO® (ritlecitinib) as a once-daily oral treatment across a wide range of disease extent.

Key Stats for UnitedHealth StockCurrent Price: $365. 20Target Price (Mid): ~$586Street Target: ~$482Potential Total Return: ~61%Annualized IRR: ~12% / yearWhat Happened?UnitedHealth Group (UNH:NYSE) is shutting Medicare Advantage plans that cover about 390,000 people for 2027, a company spokesperson told Bloomberg on October 1.

Traders are reportedly pairing Robinhood’s (NASDAQ: $HOOD) tokenized stocks with memecoins in liquidity pools...

European equities traded in the US as American depositary receipts were trending higher late Friday

Revvity (RVTY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced new data evaluating the efficacy and safety of POMBILITI® (cipaglucosidase alfa-atga) + OPFOLDA® (miglustat) in late-onset Pompe disease (LOPD) were presented at the 31st Annual Congress of the World Muscle Society (WMS), in Hiroshima, Japan.

The latest installment in BioPharma Dive’s data visualization series features a closer look at Kodiak’s stock performance and Hengrui's ties with U.S. and European drugmakers.

ANNOUNCEMENT NO. 3162 October 2026 ChemoMetec A/S has completed the share buyback programme announced in company announcement no. 309 dated 15 May 2026. The programme provided for the repurchase of up to 500,000 shares for a total consideration of up to DKK 100 million. Under the programme, ChemoMetec A/S repurchased a total of 239,950 shares for a total consideration of DKK 99,998,735. Following completion of the programme, ChemoMetec A/S holds a total of 239,950 treasury shares, corresponding

GEHC vs. SYK: Which Stock Is the Better Value Option?

Major corporations including Boeing, Eli Lilly, and McDonald’s have added the roles since 2020, the report from Crist Kolder finds.

Asian equities traded in the US as American depositary receipts were trending higher Friday morning,

Ivonescimab is currently in development as a combination drug across several types of solid tumours.